RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment

Yuan Meng, Haotian Liu, Haoran Zhu, Wanrong Zhang, Dong Sun, Xuefei Han, Ying Liu, Guangzuo LuoJournal for ImmunoTherapy of Cancer 2024 · DOI

TL;DR

Researchers have engineered a "double-gene" oncolytic adenovirus, RCAd-LTH-shPD-L1, that acts as a local factory for cancer therapy. By simultaneously lysing tumor cells, secreting anti-VEGF antibodies to normalize blood vessels, and using shRNA to silence the PD-L1 "cloaking" signal, this viral platform successfully turns "cold" immunosuppressive tumors into "hot" zones of active immune infiltration.

What Problem Does This Paper Address?

Immune Checkpoint Inhibitors (ICIs) have revolutionized oncology, but they face two major hurdles:

  1. Systemic Toxicity: Administering these drugs throughout the body often triggers severe autoimmune-like side effects in healthy organs.
  2. The "Cold" Tumor Problem: Many solid tumors have an immunosuppressive Tumor Microenvironment (TME). This environment is characterized by abnormal, leaky blood vessels (driven by VEGF) and high levels of PD-L1, which together act as a physical and chemical shield that prevents T cells from entering and attacking the tumor.

The authors sought to create a delivery system that provides potent, multi-pronged therapy directly to the tumor site, minimizing systemic exposure while "reshaping" the TME to allow the immune system to do its job.

Methods

The team built their solution on a Recombinant Oncolytic Adenovirus (RCAd) platform. Key engineering steps included:

  • Tumor Specificity: They used a human telomerase reverse transcriptase (hTERT) promoter to drive the expression of the viral E1A gene, ensuring the virus replicates only in cancer cells (which typically overexpress telomerase) and spares normal tissue.
  • The Anti-Angiogenic Punch: They inserted a DNA fragment encoding a bevacizumab-like anti-VEGF antibody (referred to as "LTH").
  • The Checkpoint Punch: They integrated a short hairpin RNA (shRNA) sequence designed to knock down the expression of PD-L1.
  • Validation: The virus's assembly and function were verified using western blotting (protein expression), ELISA (antibody secretion), and qPCR (gene knockdown).
  • In Vivo Testing: They utilized both standard immunodeficient nude mice and humanized M-NSG mice (engrafted with human PBMCs) to simulate a human-like immune response to the therapy.

Datasets

The study relied on a variety of established cell lines and animal models rather than large-scale genomic datasets:

  • Cancer Cell Lines: SGC-7901 and MGC-803 (gastric cancer), U87MG and U251MG (glioma).
  • Control Lines: RPE1 (normal human retinal cells) and GL261 (murine glioma) to test species and cell-type specificity.
  • Endothelial Cells: HUVECs were used for "tube formation" assays to measure anti-angiogenic effects.
  • Animal Models: BALB/c nude mice and humanized NOD-Prkdc^scid Il2rg^em1Smoc (M-NSG) mice.

Key Insights and Ideas

  • Vessel Normalization is Key: Excessive VEGF in tumors creates chaotic, hypoxic (low oxygen) vasculature. By delivering anti-VEGF locally, the virus reduces hypoxia (evidenced by lower HIF-1α levels) and "normalizes" the vessels, making it easier for lymphocytes to extravasate into the tumor.
  • Local Production vs. Systemic Delivery: The virus acts as a persistent local bio-factory. ELISA results showed that anti-VEGF antibody levels in the TME increased over time after infection, providing a sustained therapeutic effect that systemic injections often lack.
  • Synergistic Reshaping: The combination of viral lysis (which releases tumor antigens), PD-L1 knockdown, and vascular normalization led to a significant increase in Tumor-Infiltrating Lymphocytes (TILs), specifically CD8+ T cells.
  • Safety through Specificity: Because the virus requires the hTERT promoter to replicate, it showed no significant replication or toxicity in normal human cells (RPE1) or murine cells, and treated mice showed no significant weight loss.

Key Results

  • Tumor Suppression: In humanized mouse models of gastric cancer, the RCAd-LTH-shPD-L1 group showed the most significant reduction in tumor volume compared to viruses carrying only one of the therapeutic genes.
  • Immune Activation: The therapy significantly upregulated pro-inflammatory cytokines in the TME, including IFN-γ, IL-6, and IL-12.
  • TME Markers: Western blots showed a marked decrease in CD31 (a marker for blood vessels) and HIF-1α (a marker for hypoxia), proving the anti-angiogenic component was working as intended.
  • T Cell Phenotype: Flow cytometry revealed not just more T cells, but more activated T cells (increased Tim-3 expression) within the tumor.

Limitations and Future Work

  • Model Constraints: While humanized mice are a step up from nude mice, they still do not fully replicate the complexity of a native human immune system over long periods.
  • Adenoviral Immunity: A common challenge with oncolytic adenoviruses is that the patient's own immune system may clear the virus before it can finish its work. The paper does not deeply explore the impact of pre-existing anti-adenovirus antibodies.
  • Scope: The study focused primarily on gastric cancer and glioma. Future research is needed to see if this "double-gene" approach is equally effective in other "cold" tumors, such as pancreatic or prostate cancer.
  • Clinical Translation: Moving from a humanized mouse to a human patient requires rigorous scaling of dosage and further safety profiling of the localized antibody production.

Summary updated

Abstract

In summary, our data demonstrated that the localized delivery of anti-VEGF antibodies and shPD-L1 by engineered RCAd-LTH-shPD-L1 is a highly effective and safe strategy for cancer immunotherapy. Moreover, the data underscore the potential of combining local virotherapy and anti-angiogenic therapy with ICIs as an effective TME therapy for poorly infiltrating tumors.
BibTeX
@article{meng2024rcad,
  author = {Yuan Meng and Haotian Liu and Haoran Zhu and Wanrong Zhang and Dong Sun and Xuefei Han and Ying Liu and Guangzuo Luo},
  title = {{RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment}},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2023-007171},
}
Figure